💚 Today, on Phelan-McDermid Syndrome Awareness Day, we stand with individuals with PMS and their families.
At @Neuro_NOS, we are committed to turning groundbreaking science into meaningful treatments. Our IND-enabling program is advancing with strong momentum, bringing us steadily closer to our first-in-human clinical trial in 2027.
💚 Science brings hope. Our mission is to turn that hope into reality.
@CureSHANK #PhelanMcDermidSyndrome #PMSAwarenessDay #NeuroNOS #RareDisease #AutismResearch #DrugDevelopment #ClinicalTrials #HopeThroughScience #RareDiseaseResearch #ASD #Autism
🤖 Made with AI
Proud to share: the FDA has granted Orphan Drug Designation to BA-101 for Glioblastoma (GBM) — the most common malignant brain cancer in adults.
This is our 2nd ODD in 2025, advancing our mission to deliver targeted nitric-oxide–modulating therapies.
stocks.apple.com/AiEjITBE8Qw…
121
NeuroNOS retweeted
(Nasdaq: $XAIR)
@Neuro_NOS , a Beyond Air subsidiary, has been granted FDA Orphan Drug Designation for BA-101 in glioblastoma, one of the deadliest brain cancers. With few advances in treatment in decades, BA-101’s nitric oxide modulation approach could represent a breakthrough for patients.
prismmarketview.com/neuronos…
Glioblastoma (GBM) is the most aggressive brain cancer, with survival often measured in months despite current treatments.
At NeuroNOS, we’re developing a novel nNOS inhibitor to rebalance nitric oxide signaling that fuels tumor growth.
#NeuroNOS #Glioblastoma #braincancercure
2
181
In a landmark Redox Biology review, our CSO Prof. @haitham_amal (@NeuroNOS) with Tripathi & Kartawy highlighted how NO dysregulation drives brain disorders.
We’re building on these insights with a selective nNOS inhibitor for ASD. @Elsevier
#NeuroNOS #AutismResearch #NitricOxide
1
147
We’re proud our CSO, Prof. @haitham_amal, will speak at #Synchrony2025 on Aug 22! His nitric oxide work shapes our mission at @Neuro_NOS.
Thanks to the BRAIN foundation, @BostonChildrens, @HebrewU, and the Rosamund Stone Zander Center for advancing this dialogue
#AutismResearch
1
114
#ThrowbackThursday: Prof. @haitham_amal’s lab (our CSO) found disrupted autophagy proteins in two ASD models, driven by NO imbalance. Blocking nNOS restored normal function—reinforcing NeuroNOS’s approach to rebalance NO & tackle core ASD biology. #AutismResearch #NeuroNOS
Nitric oxide (NO) is vital in balance, too much from nNOS fuels nitrosative stress, disrupting synapses. Research by our CSO, Prof. @haitham_amal, links this to ASD. At NeuroNOS, we’re developing a selective nNOS inhibitor to restore brain balance.
#ASD #BrainHealth #NitricOxide
#ThrowbackThursday: A 2022 Free Radical Biology & Medicine paper by @haitham_amal revealed how nitric oxide disrupts NMDA receptor signaling in ASD models.
At NeuroNOS, we’re targeting that biology with our selective nNOS inhibitor.
#ASD #NitricOxide #TBT @ElsevierConnect
Lifetime autism care may exceed $4M per person (Zhao et al., 2024). Most treatments manage symptoms, few target root biology.
At NeuroNOS, we’re developing a first-in-class drug to rebalance NO signaling in ASD.
#NeuroNOS #Autism #ASD #NitricOxide #HealthEconomics
📽️Sneak peak: We spoke with three world-class scientists, joined by our two extraordinary Nobel Laureates who serve on our Scientific Advisory Board (SAB), as well as our CSO, to discuss our novel small-molecule nitric oxide inhibition platform for autism.
#NobelPrize #Autism
Proud to share that our CSO, Prof. @haitham_amal Amal, joins the #Synchrony2025 Roundtable on neuroenergetics in autism.
Excess NO → oxidative stress → mitochondrial strain. Our nNOS-targeted small molecule aims to restore balance. #NO #Autism
linkedin.com/posts/the-brain…
🔙 #ThrowbackThursday: 2023 Adv Sci paper “The NO answer for ASD” showed that nitric‑oxide modulation can reverse autism‑like behavior 👉 advanced.onlinelibrary.wiley…
@NeuroNOS is turning that insight into a first‑in‑human nNOS small‑molecule trial in 2026.
#NO #Autism #ASD
We're honored to be highlighted by @brainfdn for our work on nitric oxide modulation in #autism.
Proud to share the science — and the stage — at #Synchrony2025.
linkedin.com/feed/update/urn…
#NeuroNOS #NitricOxide #TranslationalResearch #ASD #CNS #DrugDevelopment
🎧 Prof. @haitham_amal, CSO @NeuroNOS, explains how NO dysregulation drives Phelan‑McDermid Syndrome (PMS) & how our FDA‑orphan small molecule advances to first‑in‑human trials in 2026. Watch ▶️ youtube.com/watch?v=YdKiIA4m…
#PMSF #CureSHANK #RareDisease #Autism #DrugDiscovery
@Neuro_NOS is excited to share the BIG news from the #FDA! The #FDA granted us an Orphan Drug Designation for #PhelanMcDermidSyndrome, a Neurodevelopmental Disorder Linked to #Autism #OrphanDrug #NitricOxide #PMS #RareDisease
nasdaq.com/press-release/neu…















